Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Aminoglutethimide-induced hematologic toxicity: worldwide experience.

A A Messeih, A Lipton, R J Santen

    Cancer Treatment Reports
    |September 1, 1985
    PubMed
    Summary

    Aminoglutethimide can cause low white blood cell (leukopenia) and platelet (thrombocytopenia) counts in patients. Blood cell counts typically recover after stopping the drug, but severe cases can be fatal.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    RANKL enhances the effect of an antagonist of inhibitor of apoptosis proteins (cIAPs) in RANK-positive breast cancer cells.

    Journal of bone oncology·2016
    Same author

    Effect of denosumab versus zoledronic acid in preventing skeletal-related events in patients with bone metastases by baseline characteristics.

    European journal of cancer (Oxford, England : 1990)·2015
    Same author

    Elevation in multiple serum inflammatory biomarkers predicts survival of pancreatic cancer patients with inoperable disease.

    Journal of gastrointestinal cancer·2014
    Same author

    Skeletal-related events and clinical outcomes in patients with bone metastases and normal levels of osteolysis: exploratory analyses.

    Clinical oncology (Royal College of Radiologists (Great Britain))·2012
    Same author

    Cancer treatment-induced bone loss in premenopausal women: a need for therapeutic intervention?

    Cancer treatment reviews·2012
    Same author

    Transforming growth-factor-alpha and factor-beta(1) levels in plasma and effusions from patients with cancer or hematologic malignancies.

    International journal of oncology·2011

    Area of Science:

    • Hematology
    • Clinical Pharmacology
    • Oncology

    Background:

    • Aminoglutethimide is a medication used in certain medical treatments.
    • Monitoring blood cell counts is crucial during aminoglutethimide therapy.

    Purpose of the Study:

    • To report the incidence and characteristics of hematologic toxicity associated with aminoglutethimide treatment.
    • To assess the reversibility and outcomes of aminoglutethimide-induced blood dyscrasias.

    Main Methods:

    • Retrospective analysis of 1333 patients treated with aminoglutethimide.
    • Monitoring of complete blood counts (CBCs) during and after treatment.

    Main Results:

    • An incidence of 0.9% (12/1333 patients) for marked leukopenia and/or thrombocytopenia was observed.

    Related Experiment Videos

  • Hematologic depression occurred within 7 weeks of treatment initiation.
  • Blood cell counts recovered promptly in most patients after drug cessation.

    • Conclusions:

    • Aminoglutethimide is associated with a low but significant risk of leukopenia and thrombocytopenia.
    • Early detection and drug withdrawal facilitate blood count recovery.
    • Severe cases, though rare, can lead to fatal outcomes like marrow aplasia and septicemia.